8a4t: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 12: | Line 12: | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
== Publication Abstract from PubMed == | == Publication Abstract from PubMed == | ||
SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (M(pro), 3CL(pro)) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. M(pro) is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV-2 M(pro) alpha-ketoamide inhibitor 13b. The pure (S,S,S)-diastereomer, 13b-K, displays an | SARS-CoV-2 is the causative agent behind the COVID-19 pandemic. The main protease (M(pro), 3CL(pro)) of SARS-CoV-2 is a key enzyme that processes polyproteins translated from the viral RNA. M(pro) is therefore an attractive target for the design of inhibitors that block viral replication. We report the diastereomeric resolution of the previously designed SARS-CoV-2 M(pro) alpha-ketoamide inhibitor 13b. The pure (S,S,S)-diastereomer, 13b-K, displays an IC(50) of 120 nM against the M(pro) and EC(50) values of 0.8-3.4 muM for antiviral activity in different cell types. Crystal structures have been elucidated for the M(pro) complexes with each of the major diastereomers, the active (S,S,S)-13b (13b-K), and the nearly inactive (R,S,S)-13b (13b-H); results for the latter reveal a novel binding mode. Pharmacokinetic studies show good levels of 13b-K after inhalative as well as after peroral administration. The active inhibitor (13b-K) is a promising candidate for further development as an antiviral treatment for COVID-19. | ||
Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.,Cooper MS, Zhang L, Ibrahim M, Zhang K, Sun X, Roske J, Gohl M, Bronstrup M, Cowell JK, Sauerhering L, Becker S, Vangeel L, Jochmans D, Neyts J, Rox K, Marsh GP, Maple HJ, Hilgenfeld R J Med Chem. 2022 Oct 13;65(19):13328-13342. doi: 10.1021/acs.jmedchem.2c01131., Epub 2022 Sep 30. PMID:36179320<ref>PMID:36179320</ref> | Diastereomeric Resolution Yields Highly Potent Inhibitor of SARS-CoV-2 Main Protease.,Cooper MS, Zhang L, Ibrahim M, Zhang K, Sun X, Roske J, Gohl M, Bronstrup M, Cowell JK, Sauerhering L, Becker S, Vangeel L, Jochmans D, Neyts J, Rox K, Marsh GP, Maple HJ, Hilgenfeld R J Med Chem. 2022 Oct 13;65(19):13328-13342. doi: 10.1021/acs.jmedchem.2c01131. , Epub 2022 Sep 30. PMID:36179320<ref>PMID:36179320</ref> | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
Latest revision as of 07:00, 21 November 2024
crystal structures of diastereomer (S,S,S)-13b (13b-K) in complex with the SARS-CoV-2 Mpro
| ||||||||||||